Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Research Reveals Disconnect Between Parents and Physicians in Pediatric Clinical Trial Recruitment

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Study from Blue Chip Patient Recruitment provides best practices for recruiting pediatric patients in clinical trials.

Blue Chip Patient Recruitment, a global, full-service strategic marketing practice of Blue Chip Marketing Worldwide that specializes in accelerating enrollment of clinical trials, has announced results of its latest research study on how physicians and clinical trial coordinators can successfully accelerate enrollment of pediatric clinical trials.

The white paper, titled “Accelerating Recruitment for Pediatric Clinical Trials: Connecting Parents, Children and Investigators” and available at, summarizes the results of primary market research that explores the motivations and barriers a parent faces when considering clinical trial opportunities for their child and the challenges physicians experience when recruiting children for clinical trials.

“Understanding the true motivations and worries behind a parent’s decision to enroll their child in a clinical trial is essential for successful enrollment,” says Neil Weisman, EVP/general manager of Blue Chip Patient Recruitment. “With adult conditions starting to emerge in children more frequently and since many medications have never been studied in children, sponsors and investigators will need this type of research to successfully address changing pediatric healthcare needs.”

Key findings include:

The study shows that even though parents may be very or somewhat satisfied with their child’s current medication, physicians should always educate and inform parents of potential clinical trial opportunities. Nearly 85% of the parents who were “very or somewhat satisfied” with their child’s current medication indicated they would be willing to switching their child to a new medication option.

To better connect with parents, physicians should focus on how the trial can potentially benefit their child as opposed to more altruistic-based communications. More than 53% of parents cited “my child might benefit” as their top motivation for enrolling their child in a clinical trial while 74% of physicians chose “benefit other children in the future” as their main point when educating parents on clinical trial opportunities.

Physicians need to understand and create communications based on how their patients’ parents prefer to receive information about potential pediatric clinical trial opportunities. Listed as the most preferred method of communications, 46% of parents indicated they prefer to receive information about pediatric clinical trial opportunities from their physicians by email, whereas only 6% of physicians stated that email was the most effective way to communicate with parents. And while not one doctor stated a physical letter was effective, nearly 30% of parents preferred to receive clinical trial information via a physical letter.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos